Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $181.47 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Covidien LP | $67.08 | 3 | $0 (2018) |
| Novo Nordisk Inc | $29.87 | 2 | $0 (2022) |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.14 | 1 | $0 (2022) |
| Allergan, Inc. | $13.44 | 1 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.08 | 1 | $0 (2021) |
| Innocoll Pharmaceuticals Limited | $12.56 | 1 | $0 (2022) |
| ACELL, INC. | $12.04 | 1 | $0 (2018) |
| Ethicon US, LLC | $11.26 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $64.57 | 4 | Novo Nordisk Inc ($29.87) |
| 2021 | $13.08 | 1 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($13.08) |
| 2020 | $13.44 | 1 | Allergan, Inc. ($13.44) |
| 2018 | $78.00 | 4 | Covidien LP ($54.70) |
| 2017 | $12.38 | 1 | Covidien LP ($12.38) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Diabetes | ||||||
| 02/23/2022 | Biohaven Pharmaceutical Holding Company Ltd. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: PRIMARY CARE | ||||||
| 02/07/2022 | Innocoll Pharmaceuticals Limited | XARACOLL (Drug) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: Prescription Drug | ||||||
| 01/19/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: Diabetes | ||||||
| 07/07/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Gastroenterology | ||||||
| 04/22/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2018 | Ethicon US, LLC | DERMABOND Portfolio (Device) | Food and Beverage | In-kind items and services | $11.26 | General |
| Category: Wound Closure | ||||||
| 09/25/2018 | Covidien LP | Spacemaker (Device) | Food and Beverage | In-kind items and services | $31.84 | General |
| Category: Mesh | ||||||
| 08/29/2018 | ACELL, INC. | — | Food and Beverage | Cash or cash equivalent | $12.04 | General |
| 02/16/2018 | Covidien LP | Spacemaker (Device) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Devices | ||||||
| 11/10/2017 | Covidien LP | ProGrip (Device) | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: Mesh | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 94 | 100 | $12,850 | $6,617 |
| 2022 | 2 | 36 | 36 | $10,792 | $4,318 |
| 2021 | 3 | 71 | 72 | $21,410 | $9,087 |
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $6,570 | $3,504 | 53.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 56 | $6,280 | $3,114 | 49.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 24 | 24 | $8,030 | $3,295 | 41.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 12 | 12 | $2,762 | $1,024 | 37.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 22 | 22 | $7,810 | $3,715 | 47.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 20 | 21 | $6,930 | $3,013 | 43.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 29 | 29 | $6,670 | $2,359 | 35.4% |
About Dr. Lance Bryce, MD
Dr. Lance Bryce, MD is a Surgery healthcare provider based in Brigham City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1639372840.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lance Bryce, MD has received a total of $181.47 in payments from pharmaceutical and medical device companies, with $64.57 received in 2022. These payments were reported across 11 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($181.47).
As a Medicare-enrolled provider, Bryce has provided services to 201 Medicare beneficiaries, totaling 208 services with total Medicare billing of $20,023. Data is available for 3 years (2021–2023), covering 7 distinct procedure/service records.
Practice Information
- Specialty Surgery
- Other Specialties Surgery
- Location Brigham City, UT
- Active Since 06/06/2007
- Last Updated 01/25/2010
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1639372840
Products in Payments
- Spacemaker (Device) $54.70
- Rybelsus (Drug) $29.87
- NURTEC ODT (Drug) $22.14
- UBRELVY (Drug) $13.44
- XIFAXAN (Drug) $13.08
- XARACOLL (Drug) $12.56
- ProGrip (Device) $12.38
- DERMABOND Portfolio (Device) $11.26
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.